SMC1A Antibody

What is SMC1A and why is it important in chromosome research?

SMC1A (Structural Maintenance of Chromosomes 1A) belongs to the SMC family of proteins that play critical roles in various nuclear events requiring chromosomal structural changes. SMC1A contains a myosin-like ATPase domain that functions as a molecular motor to help organize chromatin. It serves as an essential component of the cohesin complex, which facilitates chromosome cohesion during the cell cycle. The protein forms a heterodimeric complex with SMC3 that is required for metaphase progression in mitotic cells. Beyond its structural role, SMC1A participates in DNA damage repair processes, where it becomes phosphorylated by the ATM kinase following double-strand DNA breaks. This phosphorylation is crucial for the successful repair of DNA damage . The multifunctional nature of SMC1A makes it a significant target for researchers studying chromosome dynamics, DNA repair mechanisms, and cell cycle regulation.

How do I select the appropriate SMC1A antibody for my specific research application?

Selecting the appropriate SMC1A antibody requires consideration of several experimental factors:

• Target region specificity: Determine whether you need an antibody recognizing the N-terminal, C-terminal, or internal region of SMC1A. For instance, C-terminal antibodies like ABIN6972754 target the C-terminus of human SMC1A .

• Post-translational modification detection: If your research focuses on phosphorylation events, select antibodies specifically designed to recognize phosphorylated forms, such as those targeting phosphorylated Ser957 .

• Application compatibility: Ensure the antibody is validated for your intended application:

  • For protein detection: Western blotting antibodies

  • For protein localization: Immunocytochemistry/immunohistochemistry antibodies

  • For protein interactions: Immunoprecipitation antibodies

  • For chromatin studies: ChIP-seq validated antibodies

• Species reactivity: Confirm the antibody reacts with your model organism. Many SMC1A antibodies are specifically validated for human samples .

• Clonality consideration: Choose between polyclonal antibodies (broader epitope recognition, higher sensitivity) or monoclonal antibodies (higher specificity, lower batch variation) based on your experimental needs .

For initial characterization studies, a polyclonal antibody like the rabbit-derived ABIN6972754 may provide good sensitivity, while more specific applications might require monoclonal antibodies or those targeting specific modifications.

What are the optimal conditions for using SMC1A antibodies in ChIP-seq experiments?

Optimizing ChIP-seq experiments with SMC1A antibodies requires careful attention to several experimental parameters:

• Antibody selection: Use ChIP-seq validated antibodies like ABIN6972754, which has been specifically validated for this application . Ensure the antibody targets the appropriate epitope accessible in cross-linked chromatin.

• Cross-linking protocol:

  • Standard formaldehyde fixation (1% for 10 minutes at room temperature) works for most SMC1A ChIP-seq applications

  • For studying transient or weak interactions, consider dual cross-linking with disuccinimidyl glutarate (DSG) followed by formaldehyde

• Sonication optimization:

  • Fragment chromatin to 200-500 bp size range

  • Verify fragmentation efficiency through agarose gel electrophoresis

  • Adjust sonication cycles based on your specific cell type

• Immunoprecipitation conditions:

  • Use 2-5 μg of SMC1A antibody per ChIP reaction

  • Include appropriate controls: IgG negative control and histone mark positive control

  • Extend incubation time to 12-16 hours at 4°C for optimal antibody-antigen binding

• Washing stringency:

  • Include low salt, high salt, LiCl, and TE buffer washes

  • Adjust washing stringency based on antibody specificity

• Data analysis considerations:

  • Use appropriate peak-calling algorithms suitable for cohesin/SMC proteins

  • Consider the broad binding patterns characteristic of structural proteins like SMC1A

Following these guidelines will maximize the specificity and sensitivity of SMC1A ChIP-seq experiments, providing reliable insights into its genomic binding patterns.

How can I effectively validate SMC1A antibody specificity for my research?

Thorough validation of SMC1A antibody specificity is crucial for generating reliable research data:

• Western blot validation:

  • Verify a single band at ~143 kDa (SMC1A expected molecular weight)

  • Include positive controls (tissues/cells known to express SMC1A)

  • Include negative controls (SMC1A-knockdown cells)

• Peptide competition assay:

  • Pre-incubate the antibody with immunizing peptide

  • Compare signal between blocked and unblocked antibody

  • Specific antibodies will show significantly reduced signal

• Genetic knockout/knockdown validation:

  • Test antibody in SMC1A-depleted cells (siRNA, CRISPR)

  • Signal should be substantially reduced or eliminated

  • Compare with wild-type cells to confirm specificity

• Cross-reactivity assessment:

  • Test against closely related proteins (e.g., SMC1B)

  • Ensure no significant cross-reactivity with other SMC family members

• Multiple antibody comparison:

  • Use antibodies targeting different epitopes of SMC1A

  • Results should be consistent across different antibodies

  • Discrepancies may indicate off-target binding

• Immunofluorescence pattern verification:

  • Confirm expected nuclear localization

  • Verify enrichment on mitotic chromosomes during cell division

  • Observe colocalization with known interacting partners (e.g., SMC3)

How do acetylation and phosphorylation of SMC1A interact to regulate its function in normal and cancer cells?

The interplay between acetylation and phosphorylation of SMC1A represents a sophisticated regulatory mechanism with significant implications for cell cycle progression and cancer biology:

• Regulatory sites and enzymes:

  • K579 is identified as a major acetylation site in SMC1A, evolutionarily conserved across species

  • SIRT2 is the primary deacetylase that removes acetyl groups from SMC1A K579

  • CBP functions as the acetyltransferase targeting SMC1A at K579

  • Phosphorylation occurs primarily at S957 and S966, mediated by ATM kinase

• Mechanistic interactions:

  • SMC1A acetylation at K579 directly inhibits its phosphorylation at S957/S966

  • This creates a regulatory circuit where deacetylation by SIRT2 promotes phosphorylation

  • In cancer cells, SIRT2 upregulation leads to SMC1A deacetylation, increased phosphorylation, and enhanced tumor cell survival

• Functional consequences:

  • Acetylated SMC1A (K579) leads to mitotic catastrophe and inhibits tumor growth

  • Phosphorylated SMC1A promotes cancer cell proliferation and migration

  • The balance between these modifications determines cell fate during oncogenic stress

• Clinical relevance:

  • Analysis of cancer samples shows decreased SMC1A acetylation and increased phosphorylation in early-stage cancers

  • The SIRT2-SMC1A axis represents a potential therapeutic target

  • K579 acetylation status enhances chemosensitivity to anticancer drugs like 5-FU and oxaliplatin

Understanding this regulatory axis provides insights for developing targeted approaches to modulate SMC1A function in cancer treatment strategies.

What experimental approaches can detect specific post-translational modifications of SMC1A?

Detecting and quantifying specific post-translational modifications (PTMs) of SMC1A requires specialized experimental approaches:

• Phosphorylation detection techniques:

  • Phospho-specific antibodies: Use antibodies that specifically recognize phosphorylated S957/S966 sites

  • Phos-tag SDS-PAGE: Enhanced separation of phosphorylated from non-phosphorylated forms

  • LC-MS/MS analysis: For precise identification and quantification of phosphorylation sites

  • Radioactive labeling: Incorporate 32P for tracking phosphorylation events

• Acetylation detection methods:

  • Acetylation-specific antibodies: Target K579 acetylation specifically

  • Immunoprecipitation with anti-acetyl lysine antibodies: Enrich acetylated SMC1A

  • HDAC inhibitor treatment: Use NAM or TSA to enhance acetylation for detection

  • Mass spectrometry: For site-specific acetylation mapping

• Mutation-based approaches:

  • Site-directed mutagenesis: Generate K579R (non-acetylatable) or K579Q (acetylmimetic) mutants

  • Phosphomimetic mutations: Create S957D/S966D to mimic constitutive phosphorylation

  • Non-phosphorylatable mutations: Develop S957A/S966A to block phosphorylation

• Enzyme manipulation strategies:

  • SIRT2 overexpression/knockdown: Modulate deacetylation to assess downstream effects

  • ATM kinase inhibition: Block phosphorylation to evaluate functional consequences

  • CBP overexpression: Enhance acetylation for functional studies

• Live cell imaging techniques:

  • FRET-based sensors: Monitor real-time PTM dynamics in living cells

  • Fluorescently-tagged PTM-binding domains: Visualize modification patterns during cell cycle

These approaches provide complementary information about SMC1A modifications, allowing researchers to comprehensively characterize how these PTMs regulate SMC1A function in various biological contexts.

How can researchers resolve common issues with SMC1A antibody specificity in Western blot applications?

When encountering specificity issues with SMC1A antibodies in Western blot applications, consider these systematic troubleshooting approaches:

• Multiple bands or non-specific binding:

  • Blocking optimization: Test different blocking agents (5% milk, 5% BSA, commercial blockers)

  • Antibody dilution adjustment: Increase dilution to reduce non-specific binding

  • Washing stringency: Increase Tween-20 concentration (0.1% to 0.3%) or add salt to wash buffers

  • Epitope consideration: C-terminal antibodies like ABIN6972754 may provide higher specificity

  • Sample preparation: Ensure complete denaturation and use fresh reducing agents

• Weak or no signal:

  • Protein loading: Increase total protein amount (start with 25-50 μg)

  • Transfer efficiency: Optimize transfer conditions for high molecular weight proteins

  • Antibody concentration: Decrease dilution to enhance sensitivity

  • Enhanced detection: Use high-sensitivity ECL substrates or fluorescent secondary antibodies

  • Epitope accessibility: Try antibodies targeting different regions of SMC1A

• Molecular weight inconsistencies:

  • Expected MW: Verify against the ~143 kDa expected size for SMC1A

  • Post-translational modifications: Phosphorylated or acetylated forms may show subtle shifts

  • Degradation products: Add protease inhibitors to prevent proteolytic cleavage

  • Sample preparation: Ensure consistent denaturation across all samples

• Reproducibility issues:

  • Standardized protocol: Document and follow consistent procedures

  • Antibody storage: Aliquot antibodies to avoid freeze-thaw cycles

  • Positive controls: Include consistent positive controls across experiments

  • Quantitative analysis: Use housekeeping proteins for normalization

• Validation recommendations:

  • Knockdown verification: Include SMC1A-depleted samples as negative controls

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

  • Multiple antibody comparison: Test different SMC1A antibodies targeting distinct epitopes

Following these strategies will help ensure reliable and reproducible Western blot results when working with SMC1A antibodies.

What factors should be considered when analyzing contradictory results from different SMC1A antibodies?

When faced with contradictory results from different SMC1A antibodies, consider these analytical approaches to resolve discrepancies:

By systematically evaluating these factors, researchers can transform contradictory results into insights about SMC1A biology rather than experimental obstacles.

How does SMC1A dysfunction contribute to Cornelia de Lange syndrome and what research models are available?

SMC1A dysfunction plays a critical role in Cornelia de Lange syndrome (CdLS) pathogenesis, with multiple research models available to study this relationship:

• Molecular basis of SMC1A-related CdLS:

  • Mutations in SMC1A isoform A cause Cornelia de Lange syndrome type 2

  • CdLS is an inherited developmental disorder with malformations affecting multiple systems

  • Most SMC1A mutations are missense or small in-frame deletions that maintain protein expression

  • Mutations typically affect the cohesin complex function without complete loss of SMC1A

• Cellular research models:

  • Patient-derived fibroblasts: Primary cells harboring natural SMC1A mutations

  • CRISPR-engineered cell lines: Cells with specific CdLS-associated mutations

  • iPSC models: Patient-derived induced pluripotent stem cells differentiated into relevant lineages

  • SMC1A knockdown systems: siRNA or shRNA approaches to reduce expression

• Animal models for CdLS study:

  • Mouse models: Heterozygous SMC1A mutations that mimic human CdLS variants

  • Drosophila models: Mutants in SMC1 orthologs showing developmental abnormalities

  • Zebrafish models: Allow for visualization of developmental defects in real-time

• Key experimental approaches:

  • Cohesin function assays: Sister chromatid cohesion analysis in mutant contexts

  • Transcriptome profiling: RNA-seq to identify dysregulated genes

  • Chromatin structure analysis: Hi-C or similar approaches to assess 3D genome organization

  • Protein interaction studies: IP-MS to identify altered protein complexes

  • Developmental timing assays: Assess effects on cell differentiation programs

• Antibody-based investigation strategies:

  • Use specific antibodies like ABIN6972754 to assess SMC1A localization in patient samples

  • Compare wild-type versus mutant SMC1A recruitment to chromatin

  • Analyze post-translational modification patterns in CdLS contexts

  • Evaluate potential therapeutic interventions by monitoring SMC1A function

These research approaches provide complementary insights into how SMC1A dysfunction contributes to CdLS pathophysiology, potentially guiding future therapeutic strategies.

What is the significance of SMC1A phosphorylation status in cancer progression and therapeutic response?

The phosphorylation status of SMC1A represents a critical determinant in cancer biology with significant implications for therapeutic approaches:

• Cancer-associated phosphorylation patterns:

  • Downregulation of SMC1A acetylation and upregulation of phosphorylation is observed in early-stage human cancers

  • Phosphorylation at Ser957 and Ser966 is particularly relevant to oncogenic processes

  • Phosphorylated SMC1A promotes cancer cell proliferation and migration

  • TCGA datasets show correlations between SMC1A phosphorylation and cancer progression

• Molecular mechanisms in tumor development:

  • SMC1A phosphorylation helps tumor cells overcome oncogenic stress

  • Phosphorylated SMC1A supports proper chromosome segregation during mitosis

  • Non-phosphorylatable SMC1A mutants (S957A/S966A) induce spindle multipolarity

  • The balance between acetylation and phosphorylation determines cell survival under stress conditions

• Therapeutic implications:

  Therapeutic Context	SMC1A Phosphorylation Role	Clinical Significance
  Chemotherapy response	High phosphorylation correlates with resistance	SMC1A K579 acetylation enhances sensitivity to 5-FU and oxaliplatin
  Targeted therapies	Potential target for cancer-specific interventions	SIRT2 inhibitors may decrease SMC1A phosphorylation
  Biomarker utility	Indicator of tumor aggressiveness	May help stratify patients for treatment selection
  Combination approaches	Synergistic effects with DNA-damaging agents	ATM inhibitors may potentiate effects by blocking phosphorylation

• Experimental assessment approaches:

  • Phospho-specific antibodies for S957/S966 detection in clinical samples

  • Mutation-based approaches (phosphomimetic S957D/S966D vs. non-phosphorylatable S957A/S966A)

  • SIRT2 inhibitors like AGK2 to indirectly modulate SMC1A phosphorylation

  • Xenograft models comparing tumorigenic potential of cells expressing different SMC1A phosphorylation states

• Future research directions:

  • Development of direct inhibitors of SMC1A phosphorylation

  • Investigation of combinatorial approaches targeting both acetylation and phosphorylation

  • Exploration of cancer type-specific dependencies on SMC1A phosphorylation

  • Identification of biomarkers predicting response to therapies targeting this pathway

Understanding SMC1A phosphorylation provides both mechanistic insights into cancer biology and potential avenues for therapeutic intervention, particularly in colorectal cancer where this pathway has been extensively characterized .

How can single-cell approaches enhance our understanding of SMC1A function in heterogeneous cell populations?

Single-cell methodologies offer powerful new insights into SMC1A biology that are obscured in bulk population analyses:

• Single-cell technologies applicable to SMC1A research:

  • scRNA-seq: Reveals cell-specific transcriptional consequences of SMC1A dysfunction

  • scATAC-seq: Maps chromatin accessibility changes related to SMC1A activity

  • CUT&Tag/CUT&RUN at single-cell level: Profiles SMC1A binding across individual cells

  • Single-cell Hi-C: Characterizes 3D genome organization variations

  • Mass cytometry (CyTOF): Quantifies SMC1A protein and modification levels in thousands of cells

• Key research applications:

  • Cell cycle heterogeneity: Since SMC1A function is cell cycle-dependent, single-cell approaches can disentangle cycle-specific effects

  • Rare cell populations: Identify uncommon cell types particularly sensitive to SMC1A perturbation

  • Temporal dynamics: Track modification changes (phosphorylation, acetylation) throughout cell cycle progression

  • Cellular response variation: Characterize heterogeneous responses to DNA damage or oncogenic stress

• Technical considerations for antibody-based single-cell methods:

  • Antibody specificity becomes even more critical at single-cell resolution

  • Fixation protocols must balance epitope preservation with cellular permeability

  • Signal amplification strategies may be necessary for low-abundance modifications

  • Multiplexed antibody approaches allow simultaneous detection of multiple SMC1A states

• Analytical frameworks:

  • Trajectory inference to map SMC1A modification changes during cellular processes

  • Correlation analyses between SMC1A states and transcriptional outputs

  • Network modeling to identify cell type-specific interactions

  • Integration of multiple single-cell modalities for comprehensive understanding

• Potential discoveries enabled by single-cell resolution:

  • Identification of previously unrecognized SMC1A functional states

  • Characterization of cell-specific vulnerabilities to SMC1A targeting

  • Discovery of rare cell populations driving pathology in SMC1A-related disorders

  • Understanding of stochastic versus deterministic aspects of SMC1A regulation

Single-cell approaches provide unprecedented resolution to understand SMC1A function within complex tissues and heterogeneous cell populations, potentially revealing new therapeutic opportunities for targeting specific cellular contexts.

What are the latest developments in targeting the SIRT2-SMC1A axis for cancer therapy?

The SIRT2-SMC1A regulatory axis represents an emerging therapeutic target with several promising developmental avenues:

• Mechanistic rationale for therapeutic targeting:

  • SIRT2 deacetylates SMC1A at K579, promoting its phosphorylation

  • This regulatory circuit enhances cancer cell survival under stress

  • Modulation of this pathway affects chemosensitivity to standard anticancer drugs

  • SIRT2 inhibition or promotion of SMC1A acetylation induces mitotic catastrophe in cancer cells

• Current therapeutic strategies under investigation:

  • Direct SIRT2 inhibitors: Compounds like AGK2 show promise in preclinical models

  • SMC1A acetylation mimetics: Small molecules promoting K579 acetylation state

  • ATM kinase inhibitors: Block SMC1A phosphorylation at S957/S966

  • Combination approaches: SIRT2 inhibitors with conventional chemotherapeutics like 5-FU or oxaliplatin

• Preclinical evidence supporting effectiveness:

  • SMC1A K579Q (acetylmimetic) mutant significantly inhibits tumor growth in xenograft models

  • Enhanced chemosensitivity to lower doses of oxaliplatin or 5-FU when SMC1A K579 is acetylated

  • SIRT2 overexpression rescues cancer cells from chemotherapy-induced death

• Biomarker development for patient stratification:

  • SMC1A acetylation/phosphorylation ratio as potential predictive marker

  • SIRT2 expression levels correlating with therapy response

  • Mitotic spindle multipolarity as a functional readout of pathway disruption

• Technical challenges and emerging solutions:

  • Specificity concerns: Development of highly selective SIRT2 inhibitors

  • Delivery challenges: Nanoparticle-based approaches for targeted delivery

  • Resistance mechanisms: Identification of bypass pathways that may emerge

  • Combination strategies: Rational design of synergistic drug combinations

• Future research priorities:

  • Clinical trials evaluating SIRT2 inhibitors in combination with standard chemotherapy

  • Development of direct SMC1A-targeting approaches

  • Investigation of tissue-specific effects and toxicity profiles

  • Exploration of immunotherapy combinations targeting this pathway

The SIRT2-SMC1A axis represents a promising therapeutic target, particularly for cancers with evidence of upregulated SIRT2 and decreased SMC1A acetylation. Current preclinical evidence suggests potential for both standalone targeted therapies and combination approaches to enhance conventional treatment efficacy .